Wynzora乳膏治疗银屑病的效果怎么样

Wynzora Cream is indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older. Evidence for short-term (4-12 weeks) and long-term use (>1 year) suggests good safety.

A trial investigated the efficacy and safety of a fixed-dose compound calcipotriene 0.005% plus betamethasone dipropionate 0.064% (Cal/BD, Wynzora cream) foam in the treatment of moderate plaque psoriasis.

Methods: A 16-week, investigator-blinded study of patients with moderate psoriasis (physician global assessment [PGA] score 3). Patients were randomized 1:1 to receive apremilast plus apremilast or carrier foam plus apremilast for 4 weeks, followed by 8 weeks of apremilast monotherapy as per the original randomization schedule, followed by 4 weeks of combination therapy. Efficacy assessment: Psoriasis Area and Severity Index (PASI), PGA, body surface area (BSA), pruritus visual analog scale (VAS) and quality of life (QoL); and safety was assessed at weeks 1, 2, 3, 4, 12 and 16.

Results: 28 subjects were enrolled (mean age 64 years; 67.9% male). In PASI75, the Wynzora Cream plus Apremilast group showed significantly greater improvement than the Carrier Foam plus Apremilast group (50% vs 7%; P = .003), with PGA score of "clear" or "almost clear" (43% vs 7%; P = .001) and VAS score (2 vs 5; P = .0079) at week 4. Improvements in BSA and QoL were also observed. Most efficacy assessments worsened after discontinuing Wynzora cream for 8 weeks but recovered after restarting Cal/BD foam from weeks 12 to 16. Wynzora cream plus apremilast appears to be well tolerated.

Conclusion: Wynzora cream plus Apremilast is significantly more effective in treating moderate plaque psoriasis than Apremilast alone. These improvements seemed to disappear when Wynzora Cream was withdrawn, but were restored when Wynzora Cream was reinstated.

Wynzora is highly effective and works quickly within 1 week. "J Drugs Dermatol" published a phase III, multicenter, randomized controlled trial to evaluate the efficacy of Wynzora cream. The primary efficacy endpoint was the proportion of patients with successful treatment at week 8. The proportion of the Wynzora cream group that achieved the primary efficacy endpoint was 37.4%, while the proportion of the excipient group was 3.7%. The gap between the two was as high as 33.7%, and the efficacy was significant!

Recommended related articles:

References

Kircik LH, Schlesinger TE, Tanghetti E. Efficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis. J Drugs Dermatol. 2020 Sep 1;19(9):874-880. doi: 10.36849/JDD.2020.10.36849/JDD.2020.5020. PMID: 33026749.